Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Ilya Yuffa, EVP and President of Lilly USA & Global Customer Capabilities, described his prior nearly four-year role leading International markets and emphasized recent progress across Lilly's portfolio. He highlighted successful launches and growing traction outside the U.S., noting supply management and multiple new market rollouts—with obesity products and self-pay channels cited as particular areas of uptake and learning for the company.

Analysis

Market structure: Lilly (LLY) is positioned to capture incremental share in global obesity/GLP-1 markets as international launches move from supply-constrained to demand-capture mode; expect revenue acceleration over next 2-8 quarters with upside if self-pay persistence converts to reimbursed demand (TAM expansion >$10–30bn incremental over 3 years). Winners: large-cap incretin developers and manufacturing/CMO partners; losers: legacy chronic-care incumbents with price-sensitive portfolios and payers facing short-term cost inflation. This shifts pricing power modestly to manufacturers but invites payer pushback over 12–36 months.

Risk assessment: Tail risks include regulatory action (Medicare/CMS price limits or formulary exclusions) and safety signals that could compress valuation 20–40% in weeks; supply-chain or litigation shocks could similarly truncate upside. Immediate (days) impact is muted; short-term (weeks–months) driven by quarterly prints and formulary moves; long-term (quarters–years) depends on reimbursement conversion and competitive sequencing. Hidden dependencies: self-pay elasticity, international reimbursement timelines, and production scale-up cadence—each can flip growth assumptions.

Trade implications: Tactical long LLY exposure (2–3% portfolio) to capture outsized launch upside over next 6–12 months, financed via buy-write or call-spread to limit premium; consider a 6–9 month LLY 5–10% OTM call spread sized to target 30–50% ROI if launches beat. Relative trade: pair long LLY vs short UNH (0.5–1% each) for 3–9 months to exploit asymmetric manufacturer upside vs payer margin pressure. Options: buy protective 3–6 month puts if CMS pricing rumors surface; increase cash/hedges ahead of earnings and major regulatory milestones.

Contrarian angles: Consensus underestimates the stickiness of self-pay demand in affluent markets and overestimates inevitable payer capitulation — so upside may be underpriced if conversion to reimbursed status occurs within 12 months. Conversely, markets may be underpricing a regulatory clampdown risk; the mispricing window is 30–180 days around CMS/legislative moves. Historical parallels: rapid therapeutic adoption (e.g., SGLT2 class) shows spike then payer negotiation; expect similar two-phase returns rather than linear growth. Unintended consequence: heavy manufacturer pricing could accelerate policy responses that cap long-term margins, making late-stage entry expensive.

Key Decisions for Investors

• Establish a 2–3% long position in LLY equity into the next two quarterly releases to capture international obesity launch acceleration; hedge with a 6–9 month 5–10% OTM call spread to cap premium outlay and target 30–50% upside.
• Initiate a 0.5–1% pair trade: long LLY vs short UNH (UnitedHealth) for a 3–9 month horizon to exploit asymmetric upside in drug sales vs payer margin exposure; size shorts small to limit regulatory tail risk.
• Buy 3–6 month LLY protective puts (2–3% notional) if CMS issues draft guidance on GLP-1 reimbursement or if headlines indicate potential safety reviews—exit if no regulatory escalation within 60 days.
• Reduce exposure by 50% to mid/small-cap GLP-1 hopefuls within biotech holdings (names < $5bn mkt cap) and reallocate into large-cap LLY/NVO over 1–3 months; small caps face higher dilution and rollout/scale risk.
• Monitor three catalysts over the next 30–90 days and act on triggers: (1) Q1/Q2 international sales beats >+15% vs consensus, (2) CMS/Congress proposals mentioning GLP-1 pricing or formulary changes, (3) any Class safety signal—move to add or liquidate positions within 5 trading days of confirmed announcements.